<< SNY/MNTA from yahoo boards FWIW: July 28, 2010 Enoxaparin award Effective July 27 2010, Premier is pleased to announce the sole award of enoxaparin sodium (Lovenox) to Sanofi-Aventis. Sanofi-Aventis has provided Premier aggressive pricing as well as market leading Auto-sub and DSH pricing. Premier current estimated annual spend on brand Lovenox is more than $325 million. The new Sanofi-Aventis agreement for Lovenox will provide Premier members an estimated annual savings over the current base price of up to 40 percent, translating to approximately $46.3 million. How does this effect us when Premier and Novation are the two biggest hospital suppliers. >>
Not a huge surprise. I've estimated in my model a 40% U.S. market share for Sandoz and the above statement doesn't change that.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.